A startup backed by Nobel winner David Baker takes an AI twist on antibodies

Andrew Dunn

Senior Biopharma Correspondent

The newest David Baker biotech startup launched Wednesday, as Archon Biosciences has raised a $20 million seed round to develop what it believes could be …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

A startup backed by Nobel winner David Baker takes an AI twist on antibodies

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Updated: Lilly’s shares tank after trimming revenue guidance. It also cut three assets

AstraZeneca China exec probed by local authorities

Biogen signs molecular glue deal, raises yearly projections

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

GSK remains ‘very confident’ in RSV vaccine amid competition, sales slump

Sage, Biogen won't pursue major depression approval for postpartum pill

A start­up backed by No­bel win­ner David Bak­er takes an AI twist on an­ti­bod­ies

Senior Biopharma Correspondent

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

A startup backed by Nobel winner David Baker takes an AI twist on antibodies